

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

Bcl-xL (54H6) Rabbit mAb

RRID:AB_2228008

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2764, RRID:AB_2228008

Antibody Information

URL: http://antibodyregistry.org/AB_2228008

Proper Citation: Cell Signaling Technology Cat# 2764, RRID:AB_2228008

Target Antigen: Bcl-xL

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F. Consolidation on 11/2018: AB_10695729, AB_10831364, AB_2228008.

Antibody Name: Bcl-xL (54H6) Rabbit mAb

Description: This monoclonal targets Bcl-xL

Target Organism: monkey, rat, mouse, human

Clone ID: 54H6

Antibody ID: AB_2228008

Vendor: Cell Signaling Technology

Catalog Number: 2764

Record Creation Time: 20250819T230702+0000

Record Last Update: 20250820T042010+0000

Ratings and Alerts

No rating or validation information has been found for Bcl-xL (54H6) Rabbit mAb.

No alerts have been found for Bcl-xL (54H6) Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 89 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. *Cancer research*, 86(6), 1467.

Wang SZ, et al. (2026) Lipocalin 2 orchestrates resistance to ferroptosis via AXL. *Cell reports*, 45(3), 116965.

Mahama A, et al. (2026) HIV gp120 induces TREM1 expression through TLR-PGE? signalling in human monocyte-derived microglia. *Journal of neuroinflammation*, 23(1).

Tan M, et al. (2026) A Novel Niclosamide Sulfate Prodrug with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Inhibition of Multiple Signaling Pathways. *bioRxiv : the preprint server for biology*.

Li X, et al. (2026) Cordycepin alleviates ischaemic brain injury by suppressing microglia-induced neuroinflammation via regulating the Notch1 signalling pathway. *British journal of pharmacology*, 183(13), 3578.

Roleder C, et al. (2026) Cyclin-Dependent Kinase-9 and Oxidative Phosphorylation Inhibition Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma. *Cancer research communications*, 6(5), 1192.

Uprety A, et al. (2026) SETD2 Deficiency Drives Mitochondrial DNA Leakage and Creates a Druggable Dependency on BCL-xL in Clear Cell Renal Cell Carcinoma. *Cancer research*, 86(15), 3838.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. *iScience*, 28(6), 112584.

Hirani R, et al. (2025) BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways. *Cell reports*, 44(6), 115779.

Brim BC, et al. (2025) Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7-Expressing CRPC Models. *Cancer research communications*, 5(8), 1396.

Semenova G, et al. (2025) Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer. *bioRxiv : the preprint server for biology*.

Yuan L, et al. (2025) Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degradator of the Nuclear Pore Complex. *Cancer discovery*, 15(12), 2505.

Stewart ML, et al. (2025) CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia. *Cell reports. Medicine*, 102526.

Fiskus W, et al. (2025) Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. *Blood*, 145(6), 612.

Qin X, et al. (2025) Paclitaxel-induced mitotic arrest results in a convergence of apoptotic dependencies that can be safely exploited by BCL-XL degradation to overcome cancer chemoresistance. *bioRxiv : the preprint server for biology*.

Han J, et al. (2025) FGL2-induced metabolic dysregulation in enteric neural crest cells provides insight into Hirschsprung disease pathogenesis. *iScience*, 28(9), 113423.

Montuori G, et al. (2025) Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers. *Cancer discovery*, 15(10), 2054.

Panda PK, et al. (2025) BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation-Induced Apoptosis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1333.

White MC, et al. (2024) Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden. *Cancer research communications*, 4(4), 1024.

Banerjee S, et al. (2024) Neuregulin 1 Signaling Attenuates Tumor Necrosis Factor γ -Induced Female Rat Luteal Cell Death. *Endocrinology*, 165(11).